表 1.

APS患者、疾病对照组和健康对照组的临床基本资料

Demographics characteristics of APS patients, disease controls, and healthy controls

Parameters	APS patients (n=162)	Disease controls (n=122)	Healthy controls (n=50)
Data are presented as x±s or n (%). * three classic antibodies in the patient’s serum including the aCL, aβ2GPI, and LAC were all negative during test. APS, antiphospholipid syndrome; CAD, coronary artery disease; aCL, anticardiolipin antibodies; aβ2GPI, anti-β2-glycoprotein Ⅰ anti-bodies; LAC, lupus anticoagulant; aPLs, antiphospholipid antibodies; ox-LDL-Ab, oxidized low-density lipoprotein antibodies.
Age/years	41.7±15.2	48.8±16.6	42.4±10.3
Gender (female)	143 (88.3)	106 (86.9)	33 (66.0)
Thrombosis	98 (60.5)	0 (0)	0 (0)
Venous thrombosis	61 (37.7)	0 (0)	0 (0)
Deep venous thrombosis	40 (24.7)	0 (0)	0 (0)
Pulmonary embolism	19 (11.7)	0 (0)	0 (0)
Arterial thrombosis	56 (34.6)	0 (0)	0 (0)
Cerebral infarction	35 (21.6)	0 (0)	0 (0)
CAD	8 (4.9)	0 (0)	0 (0)
Atherosclerosis	47 (29.0)	0 (0)	0 (0)
Both venous and arterial thrombosis	19 (11.7)	0 (0)	0 (0)
Pregnancy morbidity	78 (48.1)	0 (0)	0 (0)
Both thrombosis and pregnancy morbidity	14 (8.6)	0 (0)	0 (0)
Livedo reticularis	1 (0.6)	0 (0)	0 (0)
Thrombocytopenia	55 (34.0)	0 (0)	0 (0)
aCL IgG/IgA/IgM (+)	29 (17.9)	0 (0)	0 (0)
aβ2GPI IgG/IgA/IgM (+)	56 (34.6)	2 (1.6)	1 (2.0)
LAC (+)	76 (46.9)	8 (6.6)	0 (0)
Double positive aPLs	29 (17.9)	0 (0)	0 (0)
Triple positive aPLs	34 (21.0)	0 (0)	0 (0)
Triple negative aPLs*	42 (25.9)	111 (91.0)	49 (98.0)
ox-LDL-Ab (+)	109 (67.3)	75 (61.5)	18 (36.0)